| Added by | mollevi |
|---|---|
| Group name | EquipeMY |
| Item Type | Journal Article |
| Title | Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab |
| Creator | Mazard et al. |
| Author | Thibault Mazard |
| Author | Piyaporn Boonsirikamchai |
| Author | Michael J. Overman |
| Author | Mohamed A. Asran |
| Author | Haesun Choi |
| Author | Delise Herron |
| Author | Cathy Eng |
| Author | Dipen M. Maru |
| Author | Marc Ychou |
| Author | Jean-Nicolas Vauthey |
| Author | Evelyne M. Loyer |
| Author | Scott Kopetz |
| Abstract | OBJECTIVE: The purpose was to validate the prognostic value of an early optimal morphological response on CT in patients treated with bevacizumab-containing chemotherapy for unresectable colorectal cancer liver metastases (CLM). It also evaluated the prognostic value of size-based criteria and the association of optimal morphological response with the receipt of bevacizumab. DESIGN: 141 patients treated first using bevacizumab and 142 patients from a randomised study evaluating the addition of bevacizumab to oxaliplatin-based chemotherapy were retrospectively analysed. Radiologists evaluated pretreatment and restaging CT scans using morphological response criteria. Responses were also assessed with size-based criteria: Response Evaluation Criteria in Solid Tumors (RECIST), early tumour shrinkage (ETS) and deepness of response (DpR). The ability of each criterion to predict progression-free survival (PFS), overall survival (OS) and postprogression survival (PPS) was determined using a univariate Cox proportional hazards model. RESULTS: In both populations, median PFS was significantly longer for patients achieving an optimal morphological response (10.4 vs 6.8 months, p=0.03; and 8.3 vs 4.9 months, p<00001, respectively). Neither RECIST nor ETS responses were associated with a prolonged PFS. Median OS was longer for those with an optimal morphological response but only at second restaging in the first population (n=141, 20.8 vs 12.3 months, p=0.002). DpR but not optimal morphological response was associated with PPS. In the randomised study, an optimal morphological response was 6.2 times more likely among patients receiving bevacizumab (p<0.0001). CONCLUSION: In patients with unresectable CLM, early morphological response may be a better predictor of PFS than size-based response. The addition of bevacizumab improves morphological response rate. |
| Publication | Gut |
| Volume | 67 |
| Issue | 6 |
| Pages | 1095-1102 |
| Date | 06 2018 |
| Journal Abbr | Gut |
| Language | eng |
| DOI | 10.1136/gutjnl-2017-313786 |
| ISSN | 1468-3288 |
| Library Catalog | PubMed |
| Extra | PMID: 29084828 |
| Tags | Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, colorectal cancer, Colorectal Neoplasms, Female, Humans, imaging, Liver Neoplasms, Male, Middle Aged, original, Prognosis, Retrospective Studies, Survival Rate, Tomography, X-Ray Computed, Treatment Outcome |
| Date Added | 2018/11/13 - 17:25:01 |
| Date Modified | 2019/05/21 - 13:19:17 |
Institut de Recherche en Cancérologie de
